KNSA

Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals International, plc (KNSA) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 D+ (1.7) B+ (3.6) B+ (3.7) A- (3.9) C+ (2.6) B- (3.1)
2026-11-06 D+ (1.7) B+ (3.7) B+ (3.7) B+ (3.8) C+ (2.7) B- (3.1)
2026-10-30 D+ (1.6) B (3.2) A- (3.9) B+ (3.8) C+ (2.7) B- (3.0)
2026-10-23 D+ (1.6) B- (3.0) B+ (3.7) A- (4.1) C+ (2.6) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe